Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025Management ViewChristophe Weber, CEO, announced his retirement ...

Corp. ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry ...

Sprinklr , the unified customer experience management (Unified-CXM) platform for modern enterprises, has appointed Jan R. Hauser, a global finance leader and retired PricewaterhouseCoopers (PwC) ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Christophe Weber will step down as CEO of Takeda next year, the company announced, following a dropoff in its share price ...

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top drugmaker.

Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. | Takeda has named Julie Kim ...

Biote said Chief Executive Officer Terry Weber is expected to retire effective Feb. 1, and would be succeeded by Bret Christensen. The hormone- and therapeutic-health and wellness company said Weber ...

Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's ...

Takeda (TAK) announced that its board of directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S.

Takeda Pharmaceutical Company Limited ( NYSE: TAK) Q3 2025 Results Conference Call January 30, 2025 5:30 AM ET Christopher O’Reilly - Head, Investor Relations Christophe Weber - President and Chief ...